MX2022011893A - Nuevos analogos de il-2 inmunoestimuladores. - Google Patents

Nuevos analogos de il-2 inmunoestimuladores.

Info

Publication number
MX2022011893A
MX2022011893A MX2022011893A MX2022011893A MX2022011893A MX 2022011893 A MX2022011893 A MX 2022011893A MX 2022011893 A MX2022011893 A MX 2022011893A MX 2022011893 A MX2022011893 A MX 2022011893A MX 2022011893 A MX2022011893 A MX 2022011893A
Authority
MX
Mexico
Prior art keywords
interleukin
analog
immunoactive
novel
receptor binding
Prior art date
Application number
MX2022011893A
Other languages
English (en)
Inventor
Jin Young Kim
Euh Lim Oh
Yong Ho Heo
Sang Yun Kim
Cho Rong Park
Jun Sub Park
Hyun Soo Ryu
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2022011893A publication Critical patent/MX2022011893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a cambios en los receptores alfa de interleucina 2 y análogos de interleucina 2 con mayor afinidad de unión por los receptores beta de interleucina 2.
MX2022011893A 2020-03-31 2021-03-31 Nuevos analogos de il-2 inmunoestimuladores. MX2022011893A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200039476 2020-03-31
PCT/KR2021/004028 WO2021201615A1 (ko) 2020-03-31 2021-03-31 신규한 면역 활성 인터루킨 2 아날로그

Publications (1)

Publication Number Publication Date
MX2022011893A true MX2022011893A (es) 2022-10-18

Family

ID=77930406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011893A MX2022011893A (es) 2020-03-31 2021-03-31 Nuevos analogos de il-2 inmunoestimuladores.

Country Status (16)

Country Link
US (2) US11746137B2 (es)
EP (1) EP4130027A4 (es)
JP (2) JP2023515247A (es)
KR (2) KR102545250B1 (es)
CN (2) CN115427437B (es)
AR (1) AR121713A1 (es)
AU (2) AU2021202825B2 (es)
BR (1) BR112022018730A2 (es)
CA (1) CA3169564C (es)
CL (1) CL2022002562A1 (es)
IL (1) IL295826B2 (es)
MX (1) MX2022011893A (es)
PE (1) PE20221759A1 (es)
TW (1) TWI876021B (es)
WO (1) WO2021201615A1 (es)
ZA (1) ZA202209565B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011893A (es) * 2020-03-31 2022-10-18 Hanmi Pharm Ind Co Ltd Nuevos analogos de il-2 inmunoestimuladores.
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20230303649A1 (en) 2021-07-09 2023-09-28 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
KR20230095612A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
KR102445492B1 (ko) * 2021-12-24 2022-09-21 엔케이젠 주식회사 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법
IL317511A (en) * 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
CN119790064A (zh) * 2022-08-23 2025-04-08 马斯得生物有限公司 Il2变体和包括该il2变体的蛋白复合体
KR20250126198A (ko) 2024-02-15 2025-08-25 한림대학교 산학협력단 인슐린 저항성의 예방 또는 치료를 위한 약학적 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004665A2 (en) 1987-11-25 1989-06-01 Cetus Corporation Treatment of infections caused by a primary immunodeficiency with interleukin-2
JPH03500415A (ja) * 1988-07-05 1991-01-31 アムジエン・インコーポレーテツド インターロイキン２類似体
CA2019714A1 (en) * 1989-06-27 1990-12-27 Richard A. Chizzonite Process for the determination of interleukins
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
ATE464062T1 (de) * 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
WO2005007121A2 (en) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
AU2007201663A1 (en) * 2007-04-16 2008-10-30 Nautilus Biotech Oral dosage formulations of protease resistant polypeptides
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
JP6093712B2 (ja) * 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
PE20151409A1 (es) 2013-02-26 2015-10-07 Hanmi Pharm Ind Co Ltd Analogo de insulina novedoso y su uso
WO2015042707A1 (en) * 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
US10253082B2 (en) 2014-01-20 2019-04-09 Hanmi Pharm. Co., Ltd Long-acting insulin and use thereof
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
RU2020142556A (ru) 2014-10-21 2021-02-12 Сайклон Фармасьютикалз Интернешнл Лтд. Способ лечения рака или его метастаза с помощью пептида тимозина-альфа и ингибитора белка запрограммированной гибели клеток-1 (pd-1)
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
KR20160134989A (ko) 2015-05-14 2016-11-24 순천향대학교 산학협력단 인간 인터류킨-2 단백질을 포함하는 약학조성물
CN107266553A (zh) * 2016-04-08 2017-10-20 南京康志制药有限公司 高效人白细胞介素ⅱ突变体融合蛋白及其应用
CN109071623B (zh) * 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
AU2018226857B2 (en) * 2017-03-03 2025-01-02 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
CN111094356B (zh) * 2017-09-25 2022-11-01 苏州丁孚靶点生物技术有限公司 一种蛋白质异二聚体及其用途
US10946068B2 (en) * 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN112105632A (zh) * 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白
CN108503714A (zh) * 2018-04-10 2018-09-07 浙江科途医学科技有限公司 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
DK3794024T5 (da) * 2018-05-14 2024-08-19 Werewolf Therapeutics Inc Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
CN112638406B (zh) 2018-06-22 2025-04-22 科优基因公司 白介素-2变体及其使用方法
JP7550745B2 (ja) 2018-07-24 2024-09-13 バイオエヌテック エスエー Ｉｌ２アゴニスト
CA3086486A1 (en) * 2018-09-17 2020-03-26 Gi Innovation, Inc. Fusion protein comprising il-2 protein and cd80 protein, and use thereof
TWI791894B (zh) * 2018-09-21 2023-02-11 大陸商信達生物製藥（蘇州）有限公司 新型白介素２及其用途
MY205758A (en) * 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
KR20200078312A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN111018961B (zh) 2019-12-17 2022-03-18 北京志道生物科技有限公司 白介素-2衍生物
AU2021231869A1 (en) * 2020-03-05 2022-09-15 The Board Of Trustees Of The Leland Stanford Junior University Designed IL-2 variants
MX2022011893A (es) * 2020-03-31 2022-10-18 Hanmi Pharm Ind Co Ltd Nuevos analogos de il-2 inmunoestimuladores.

Also Published As

Publication number Publication date
US11746137B2 (en) 2023-09-05
AR121713A1 (es) 2022-06-29
ZA202209565B (en) 2023-12-20
CA3169564A1 (en) 2021-10-07
KR102545250B1 (ko) 2023-06-21
WO2021201615A1 (ko) 2021-10-07
EP4130027A1 (en) 2023-02-08
CL2022002562A1 (es) 2023-03-17
IL295826A (en) 2022-10-01
AU2021202825B2 (en) 2022-06-30
US20230348550A1 (en) 2023-11-02
AU2022203841A1 (en) 2022-06-23
PE20221759A1 (es) 2022-11-11
IL295826B1 (en) 2025-07-01
US12415842B2 (en) 2025-09-16
AU2021202825A1 (en) 2021-10-14
IL295826B2 (en) 2025-11-01
KR20230088656A (ko) 2023-06-20
TW202204387A (zh) 2022-02-01
KR20210122200A (ko) 2021-10-08
CN115427437A (zh) 2022-12-02
US20230124171A1 (en) 2023-04-20
CA3169564C (en) 2025-05-06
JP2023515247A (ja) 2023-04-12
EP4130027A4 (en) 2024-08-14
CN118271419A (zh) 2024-07-02
BR112022018730A2 (pt) 2022-11-01
JP2024041747A (ja) 2024-03-27
CN115427437B (zh) 2024-04-19
TWI876021B (zh) 2025-03-11

Similar Documents

Publication Publication Date Title
MX2022011893A (es) Nuevos analogos de il-2 inmunoestimuladores.
IL290598A (en) Modified interleukin 2 (il-2) polypeptides, conjugates and uses them
MX2025003080A (es) Conjugados de il-15, y sus usos
MX2023004349A (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
ZA202106602B (en) Claudin 6 antibodies and uses thereof
MY206440A (en) Bacillus subtilis cjbs303 and composition comprising same
PH12022500003A1 (en) Il-2 conjugates and methods of use to treat autoimmune diseases
WO2023288241A8 (en) Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
MX2020011133A (es) Composiciones de pienso para animales y usos de las mismas.
PH12022550165A1 (en) Interleukin-2 agents and uses thereof
MX2022000369A (es) Cepa bacteriana de bifidobacterium bifidum, las composiciones de la misma y usos relacionados.
MX2023006596A (es) Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma.
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
EP4242295A3 (en) B. amyloliquefaciens strain and therapeutic use
SG11202000123SA (en) Lactobacillus plantarum cjlp475 strain having antiviral and immunomodulatory effects and composition comprising the same
PH12021553101A1 (en) Natriuretic peptide receptor 1 antibodies and methods of use
JOP20230239A1 (ar) أجسام مضادة للنكتين-4 واستخدامتها
GB202218419D0 (en) Sirp alpha and sirp beta 1 antibodies and uses thereof
MX2019003543A (es) Anticuerpos que se fijan al interleucina-2 y sus usos.
MX2023010926A (es) Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo.
EP4647437A3 (en) Immunostimulatory compositions
MX2023005113A (es) Cápsides de aav y composiciones que las contienen.
MX2022010990A (es) Variantes dise?adas de il-2.
MX2024000324A (es) Usos de un microorganismo de bifidobacterium longum de transicion.
SG11202000113QA (en) Composition comprising lactobacillus plantarum cjlp475 strain and lactobacillus plantarum cjlp243 strain and use thereof